Transitional cell carcinoma refers to a cancer that originates in the urothelial cells lining the urinary tract and other organs. It can occur in the ureters, bladder, renal pelvis, or other organs. Upper urinary tract transitional cell carcinoma makes up 5% of urothelial cancers and less than 10% of kidney tumors, with the evidence indicating an increasing incidence. Thus, the rising burden of transitional cell carcinoma along with the growing regulatory support in the form of faster approval pathways and incentives for orphan drugs is anticipated to expedite the drug pipeline growth in the coming years.
The Transitional Cell Carcinoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into transitional cell carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for transitional cell carcinoma. The transitional cell carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The transitional cell carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with transitional cell carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to transitional cell carcinoma.
Transitional cell carcinoma accounts for the majority of bladder cancer cases and primarily affects the lining of the urinary tract, including the bladder, ureters, and renal pelvis. Smoking, exposure to industrial chemicals, chronic bladder inflammation, and certain genetic predispositions include the risk factors of transitional cell carcinoma. The prognosis depends on the stage and grade of the tumor.
Transitional cell carcinoma treatments include a combination of chemotherapy, surgery, radiation, and immunotherapy. Drugs like pembrolizumab (anti-PD-1) and atezolizumab (anti-PD-L1) that enhance the ability of the immune system to attack cancer cells are increasingly being used by patients. Further, the rising focus on the development of drugs targeting specific genetic mutations or molecular pathways is expected to support the pipeline expansion in the coming years.
Studies show that transitional cell carcinoma of the renal pelvis accounts for about 7% of all kidney tumor cases. On the other hand, transitional cell carcinoma of the ureter represents nearly 4% of upper urinary tract tumors. It is estimated that 90% of patients can be cured if their tumors are superficial and confined to the ureter or renal pelvis.
This section of the report covers the analysis of transitional cell carcinoma drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials, with a substantial number of transitional cell carcinoma drugs undergoing clinical development.
The drug molecule categories covered under transitional cell carcinoma pipeline analysis include small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), peptides, cell and gene therapies, RNA-based therapies, and viral-based therapies. The transitional cell carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for transitional cell carcinoma.
The EMR report for the transitional cell carcinoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed transitional cell carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in transitional cell carcinoma clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by UroGen Pharma Ltd., the objective of this multicenter clinical trial is to investigate the efficacy and safety of the transitional cell carcinoma drug candidate UGN-103 in patients with low-grade intermediate-risk non-muscle invasive bladder cancer. The study is under Phase III clinical development and has an estimated 87 participants.
Merck Sharp & Dohme LLC is conducting a Phase I/II study aimed at examining the efficacy of investigational agents with or without the combination of pembrolizumab for the treatment of PD-1/L1 refractory locally advanced or metastatic urothelial carcinoma. The interventional study has enrolled about 40 subjects and is expected to be completed by October 2028.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Transitional Cell Carcinoma Drug Report provides a strategic overview of the latest and future landscape of treatments for transitional cell carcinoma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within transitional cell carcinoma pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share